MOLECULAR GENETIC ANALYSIS OF MEASLES VIRUSES CIRCULATING IN BULGARIA DURING THE YEAR 2024
DOI:
https://doi.org/10.58395/ra3bpd74Keywords:
measles, real-time PCR, Sanger sequencingAbstract
Background: Measles is a well-known fever-rash viral disease and remains a significant public health challenge, as cases have rapidly increased in the past few years. From 1 November 2023 to 31 October 2024, 30 EU/EEA Member States reported 18 044 measles cases, of which 13 863 (76.8%) were laboratory-confirmed.
Aim: The study aimed to monitor the circulation of wild-type measles viruses (MeV) in Bulgaria in 2024.
Materials and Methods: During the MeV outbreak in the country in 2024, 126 clinical samples (63 nasal swabs and 63 urine) from 63 patients with a possible measles infection were investigated. Viral RNA was extracted using real-time PCR and conventional one step RT-PCR assays, and the nucleoprotein (N) gene from the viral genome was detected. The MeV-positive samples were sequenced by direct Sanger sequencing. Phylogenetic analysis was performed using the software program MEGA v. 11.
Results: Acute measles infection was proved in 26 out of 63 tested individuals (41%). The affected were mostly children aged 1-4 (12/26, 46%) and 5-9 years (6/26, 23%). Our studies have established nasal swabs as a more biologically applicable material for rapid PCR diagnostics of MeV, and in all patients confirmed clinically and epidemiologically, the virus was detected in their nasopharynx. The affected regions of the country were Varna (20/26), Sofia city (3/26), and single cases in Sofia district (1/26), Stara Zagora (1/26) and Burgas (1/26). In 2024, phylogenetic analysis of MeV sequences showed a predominant circulation of the D8 and B3 genotypes with imports of the viral strains from the United Kingdom, Germany, Romania, and Austria.
Conclusion: Despite the wide availability of effective vaccines, measles outbreaks continue to occur due to imported cases and transmission of the virus among unvaccinated children in communities.
Downloads
References
1. “Genus: Morbillivirus | ICTV.” Accessed: Jan. 16, 2025. [Online]. Available: https://ictv.global/report/chapter/paramyxoviridae/paramyxoviridae/morbillivirus
2. CDC, “Measles Symptoms and Complications,” Measles (Rubeola). Accessed: Mar. 20, 2025. [Online]. Available: https://www.cdc.gov/measles/signs-symptoms/index.html
3. W. J. Bellini et al., “Subacute sclerosing panencephalitis: More cases of this fatal disease are prevented by measles immunization than was previously recognized,” J. Infect. Dis., vol. 192, no. 10, pp. 1686–1693, Nov. 2005, https://doi.org/10.1086/497169.
4. S. Krumova, I. Andonova, R. Stefanova, G. Nenkova, and P. Genova-Kalou, “Measles Virus and Subacute Sclerosing Panencephalitis,” Clin. Lab., vol. 68, no. 9, Sep. 2022, https://doi.org/10.7754/Clin.Lab.2021.211147.
5. “report.knit.” Accessed: Mar. 20, 2025. [Online]. Available: https://measles-rubella-monthly.ecdc.europa.eu/
6. “European Regional Verification Commission for Measles and Rubella Elimination (RVC).” Accessed: Mar. 20, 2025. [Online]. Available: https://www.who.int/europe/groups/european-regional-verification-commission-for-measles-and-rubella-elimination-rvc
7. O. Perrone and H. C. Meissner, “The importance of MMR immunization in the United States,” Pediatrics, vol. 146, no. 2, Aug. 2020, https://doi.org/10.1542/PEDS.2020-0251.
8. CDC, “Genetic Analysis of Measles Viruses,” Measles (Rubeola). Accessed: Mar. 20, 2025. [Online]. Available: https://www.cdc.gov/measles/php/laboratories/genetic-analysis.html
9. D. Williams et al., “Update: circulation of active genotypes of measles virus and recommendations for use of sequence analysis to monitor viral transmission”.
10. “MeaNS2:” Accessed: Mar. 20, 2025. [Online]. Available: https://who-gmrln.org/means2
11. “Frontiers | Genomic tools for post-elimination measles molecular epidemiology using Canadian surveillance data from 2018–2020.” Accessed: Mar. 20, 2025. [Online]. Available: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1475144/full
12. K. R. Stanoeva, R. H. G. Kohl, and R. Bodewes, “Co-detection of the measles vaccine and wild-type virus by real-time PCR: public health laboratory protocol,” Access Microbiol., vol. 3, no. 11, p. 000283, Nov. 2021, https://doi.org/10.1099/acmi.0.000283.
13. “Web based data collection and dissemination system for epidemiological surveillance of Measles, Mumps and Rubella in Bulgaria.” Accessed: Mar. 20, 2025. [Online]. Available: https://mmr.gateway.bg/en/
14. “BLAST: Basic Local Alignment Search Tool.” Accessed: Jan. 29, 2025. [Online]. Available: https://blast.ncbi.nlm.nih.gov/Blast.cgi
15. “MEGA11: Molecular Evolutionary Genetics Analysis Version 11 | Molecular Biology and Evolution | Oxford Academic.” Accessed: Jan. 29, 2025. [Online]. Available: https://academic.oup.com/mbe/article/38/7/3022/6248099
16. “6.3 Measles RNA detection by RT-PCR,” TechNet-21. Accessed: Mar. 20, 2025. [Online]. Available: https://www.technet-21.org/en/manual-introduction/chapter-6-detection-of-viral-rna-by-rt-pcr-for-the-confirmation-of-measles-and-rubella-infection/6-3-measles-rna-detection-by-rt-pcr
17. “Chapter 10. Laboratory support for the verification of elimination of measles and rubella - TechNet-21.” [Online]. Available: https://www.technet-21.org/en/manual-introduction/chapter-10-laboratory-support-for-the-verification-of-elimination-of-measles-and-rubella
18. “Measles and Rubella Laboratory Network.” Accessed: Mar. 20, 2025. [Online]. Available: https://www.who.int/europe/initiatives/measles-and-rubella-laboratory-network
19. “report.knit.” Accessed: Apr. 04, 2025. [Online]. Available: https://measles-rubella-monthly.ecdc.europa.eu/
20. “European Region reports highest number of measles cases in more than 25 years – UNICEF, WHO/Europe.” Accessed: Mar. 20, 2025. [Online]. Available: https://www.unicef.org/press-releases/european-region-reports-highest-number-measles-cases-more-25-years-unicef-whoeurope
21. “Measles.” Accessed: Apr. 04, 2025. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/measles
22. A. A. Minta, “Progress Toward Measles Elimination — Worldwide, 2000–2022,” MMWR Morb. Mortal. Wkly. Rep., vol. 72, 2023, https://doi.org/10.15585/mmwr.mm7246a3.
23. A. A. Minta et al., “Progress Toward Measles Elimination — Worldwide, 2000–2023,” Morb. Mortal. Wkly. Rep., vol. 73, no. 45, pp. 1036–1042, Nov. 2024, https://doi.org/10.15585/mmwr.mm7345a4.
24. B. Bankamp, G. Kim, D. Hart, Beck, A.; M. Ben Mamou, A. Penedos, Y. Zhang, R. Evans, P.A. Rota. Global Update on Me asles Molecular Epidemiology. Vaccines 2024, 12, 810. https://doi.org/10.3390/vaccines12070810
25. S. Krumova, S. Santibanez, I. Andonova, R. Stefanova, A. Mankertz, and T. Kantardjiev, “Detection of measles virus in Bulgaria from 2012 to 2018,” Croat. Med. J., vol. 63, no. 5, pp. 475–481, Oct. 2022, https://doi.org/10.3325/cmj.2022.63.475.
26. W.-H. W. Lin, A. J. Tsay, E. N. Lalime, A. Pekosz, and D. E. Griffin, “Primary differentiated respiratory epithelial cells respond to apical measles virus infection by shedding multinucleated giant cells,” Proc. Natl. Acad. Sci. U. S. A., vol. 118, no. 11, p. e2013264118, Mar. 2021, https://doi.org/10.1073/pnas.2013264118.
27. G. Khan, H. O. Kangro, P. J. Coates, and R. B. Heath, “Inhibitory effects of urine on the polymerase chain reaction for cytomegalovirus DNA,” J. Clin. Pathol., vol. 44, no. 5, pp. 360–365, May 1991, https://doi.org/10.1136/jcp.44.5.360.
28. D. L. T. Benito, “Inhibit inhibition: PCR inhibition and how to prevent it,” BioEcho Life Sciences GmbH. Accessed: Apr. 04, 2025. [Online]. Available: https://www.bioecho.com/blog/inhibit-inhibition-pcr-inhibition-and-how-to-prevent-it?utm_source=chatgpt.com
29. V. A. Chayeb et al., “Development and Evaluation of a New Measles Detection Assay Using Real-Time RT-PCR,” Int. J. Mol. Sci., vol. 26, no. 5, Art. no. 5, Jan. 2025, https://doi.org/10.3390/ijms26051801.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Stefka Krumova, Lora Veleva, Radostina Stefanova, Marina Doncheva (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
